<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190917044792N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-11-15</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>The effect of using high-flow nasal cannula after early extubation respiratory  after children's heart surgery</public_title>
      <acronym></acronym>
      <scientific_title>The effect of using high-flow nasal cannula after early extubation On respiratory parameters and pulmonary complications after children's heart surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42209</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Simple random method using statistical software.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Postoperative pulmonary complications.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: From the Fisher &amp; Paykel MR850 Series we select two types of nasal cannula based on baby weight and body mass index: nasal cannula that offers maximal flow rate of 8 l / min for infants less than 4 kg and nasal cannula That delivers a maximum flow of 20 l / min for children&gt; 4 kg.And so when applied to an HFNC device, the gas mixture is set at 2 liters / kg for the first ten kilos and half liters / kg thereafter at 40% fiO2. Intervention 2: Control group:  Routinely receive normal nasal cannula section with Lit / min6 flow which produces 40% fio2.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main outcome or the like, can be shared.

When:
Start of access period 6 months after printing results

To whom:
Researchers and students will be available at academic and scientific institutions

Conditions:
Nursing care for children undergoing heart surgery

Where to obtain:
Farzaneh Enayati
Email address: enayatifarzaneh26@gmail.com

How to obtain:
Almost 1 month after sending the request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farzaneh Enayati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 3 , Elahieh 32,Elahieh Boulevard،Mashhad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9189864398</zip>
        <telephone>+98 51 3501 6559</telephone>
        <email>enayatifarzaneh26@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mojgan Ansari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Campus of Sabzevar University of Medical Sciences، Tohid Township,Sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>91898 64398</zip>
        <telephone>009851444018345</telephone>
        <email>mojganansari01@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children older than one month and less than two years old
Children with congenital heart problems based on RACHS 2 or 3 criteria
Full conscious</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>24 months</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of renal Disease
History of pulmonary disease
History of brain disease
History of Endocrine Disease
Preoperative infection history
Pre-operative mechanical ventilation
Moderate to severe anemia (hemoglobin less than 10 mg / dL)
Severe electrolyte and acid-base disturbances (pH lower than 7.30 and greater than 7.50)
Malnutrition</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T81.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified complication of procedure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: From the Fisher &amp; Paykel MR850 Series we select two types of nasal cannula based on baby weight and body mass index: nasal cannula that offers maximal flow rate of 8 l / min for infants less than 4 kg and nasal cannula That delivers a maximum flow of 20 l / min for children&gt; 4 kg.And so when applied to an HFNC device, the gas mixture is set at 2 liters / kg for the first ten kilos and half liters / kg thereafter at 40% fiO2.</i_keyword>
      <i_keyword>Control group:  Routinely receive normal nasal cannula section with Lit / min6 flow which produces 40% fio2</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Atelectasis is the sleeping or closing of the alveoli. Timepoint: Evaluation of atelectasis is monitored and recorded daily using plain chest x-ray on arrival at the ICU as well as by ultrasound. Method of measurement: Used for the evaluation of pulmonary complications, including atelectasis, a portable SonoSite EDGE ultrasound system with a pediatric size probe.</prim_outcome>
      <prim_outcome>Arterial Oxygen Pressure: Oxygen pressure (Po2) is an indirect measure of arterial blood oxygen content and its normal range is between 80-100 mmHg. Timepoint: On admission to the ICU and after 6 hours in the ICU during mechanical ventilation and before extubation and immediately after extubation and at 1, 2, 6, 12, 24 and 36 hours after HFNC or conventional oxygen therapy, respectively.will be measured. Method of measurement: Arterial blood pressure was measured using an arterial blood sample and a GEM3000 blood gas analyzer.</prim_outcome>
      <prim_outcome>Arterial carbon dioxide pressure: The relative pressure of CO2 in arterial blood is called Pco2, which is a sign of ventilation. Normal body Pco2 ranges from 35 to 45 mm Hg in adults and 41 to 26 mm Hg in children younger than 2 years. Timepoint: On admission to the ICU and after 6 hours in the ICU during mechanical ventilation and before extubation and immediately after extubation and at 1, 2, 6, 12, 24 and 36 hours after HFNC or conventional oxygen therapy, respectively.will be measured. Method of measurement: Arterial blood pressure was measured using an arterial blood sample and a GEM3000 blood gas analyzer.</prim_outcome>
      <prim_outcome>PAO2 / FIO2 Ratio: The ratio of arterial oxygen pressure and tail oxygen content, a comparison between the level of oxygen in the blood and the oxygen concentration that breathes. Normal PaO2 content: FiO2 = 100 mmHg / 500 0.2 0.21. Timepoint: On admission to the ICU and after 6 hours in the ICU during mechanical ventilation and before extubation and immediately after extubation and at 1, 2, 6, 12, 24 and 36 hours after HFNC or conventional oxygen therapy, respectively.will be measured. Method of measurement: Arterial blood samples and GEM3000 blood gas analyzer are used.</prim_outcome>
      <prim_outcome>Re-intubation: Inability to spontaneously breathe after removal of the artificial airway, leading to the need for endotracheal intubation over a specified period of time: either within 24-72 hours or up to 7 days after the first extubation. Timepoint: In this study, 24 to 72 hours after the first extubation is considered to assess the need for re-intubation. Method of measurement: According to the information recorded in the patient's file.</prim_outcome>
      <prim_outcome>Respiratory insufficiency: A sudden and dangerous impairment of gas exchange by the lungs, with the lungs failing to balance oxygen and carbon dioxide, with arterial oxygen pressure less than 50 mm Hg and arterial carbon dioxide pressure greater than 50 mm Hg and arterial pH are less than 7.35. Timepoint: Case studiesSigns and symptoms are constantly monitored for respiratory failure during the study. Method of measurement: According to respiratory parameters and arterial blood sample and analyzed with GEM3000 blood gas device.</prim_outcome>
      <prim_outcome>Pleural effusion: The fluid accumulates more than 15 cc in the lateral cavity. Timepoint: Evaluation of pleural effusion is monitored and recorded daily using plain chest x-ray and ultrasound. Method of measurement: To evaluate pulmonary complications such as pleural effusionA Portable SonoSite EDGE portable ultrasound system with a baby size probe is used.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-06</approval_date>
        <contact_name>Ethics Committee of Sabzevar University of Medical Sciences Research</contact_name>
        <contact_address>No. 3 ،Elahieh32 ،Elahieh Blv، Misaq highway،Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
